Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model: For a Hypothetical Managed-Care Plan of 100 000 Members

Author： Tan H.L.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.17, Iss.1, 2000-01, pp. : 77-107

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Patient-Level Estimates of the Cost of Complications in Diabetes in a Managed-Care Population

By Ramsey S.D.  

PharmacoEconomics, Vol. 16, Iss. 3, 1999-09 ,pp. : 285-295

Adis International

Access to resources Recommend Favorite

Phosphodiesterase-5 inhibitors for male erectile dysfunction

By Sui Zhihua  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 9, 2003-09 ,pp. : 1373-1388

Informa Healthcare

Access to resources Recommend Favorite

18 health plans from 12 top US markets have been found to provide the highest satisfaction overall among members of managed-care organisations

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 343, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Annual Cost of Erectile Dysfunction to UK Society

By Plumb J.M.   Guest J.F.  

PharmacoEconomics, Vol. 16, Iss. 6, 1999-12 ,pp. : 699-709

Adis International

Access to resources Recommend Favorite

Economic aspects of medical erectile dysfunction therapies

By Anastasiadis Aristotelis G   Ghafar Mohamed A   Shabsigh Ridwan   Burchardt Martin  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 257-263

Informa Healthcare

Access to resources Recommend Favorite